Icecure Medical (ICCM) has released an update.
IceCure Medical Ltd. has announced FDA clearance for its XSense™ Cryoablation System, a minimally invasive treatment that freezes and destroys tumors. The system, which uses liquid nitrogen, is approved for a variety of indications, enhancing patient recovery and offering a convenient procedure for healthcare providers. This technology underscores IceCure’s commitment to advancing cryoablation therapy systems for cancer treatment, including in breast and kidney cancers.
For further insights into ICCM stock, check out TipRanks’ Stock Analysis page.
